2022 | Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial | Brose, Marcia S; Robinson, Bruce G; Sherman, Steven I; Jarzab, Barbara; CHIA-CHI LIN ; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Sen, Suvajit; Oliver, Jennifer W; Banerjee, Kamalika; Keam, Bhumsuk; Capdevila, Jaume | Cancer | 14 | | |
2024 | Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study | Capdevila, Jaume; Krajewska, Jolanta; Hernando, Jorge; Robinson, Bruce; Sherman, Steven I; Jarzab, Barbara; CHIA-CHI LIN ; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Williamson, Denise; Levytskyy, Roman; Oliver, Jennifer; Keam, Bhumsuk; Brose, Marcia S | Thyroid : official journal of the American Thyroid Association | | | |